Literature DB >> 16959435

Pathological findings of uterine leiomyomas and adenomyosis following uterine artery embolization.

Pavel Dundr1, Michal Mára, Jana Masková, Zuzana Fucíková, Ctibor Povỳsil, Daniel Tvrdík.   

Abstract

Uterine artery embolization (UAE) is an effective and accepted treatment option for symptomatic uterine leiomyoma. Between 2000 and 2005, 91 women were treated using this method, and were prospectively followed at our institution. Twenty of them subsequently underwent surgery. One of these patients was subjected to four surgical procedures. We describe the pathological findings of 23 surgical specimens obtained from these 20 patients. The embolic material used consisted of tris-acryl gelatin microspheres (TGMS) in 15 patients (18 surgical specimens), polyvinyl alcohol particles (PVA) in three patients, and a combination of PVA and TGMS in two patients. Histologically, of the 23 specimens examined, 20 were diagnosed as leiomyomas, and three as adenomyosis. Particles used for embolization were found in all but three specimens. Necrosis was present in 15 of 20 leiomyoma specimens. Hyaline necrosis was found in 12 specimens, coagulative necrosis in one case, and a combination of hyaline and coagulative or suppurative necrosis in two cases. The foci of adenomyosis remained unaltered.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16959435     DOI: 10.1016/j.prp.2006.07.001

Source DB:  PubMed          Journal:  Pathol Res Pract        ISSN: 0344-0338            Impact factor:   3.250


  2 in total

1.  Uterine artery embolization for the treatment of adenomyosis.

Authors:  Meridith J Englander
Journal:  Semin Intervent Radiol       Date:  2008-12       Impact factor: 1.513

Review 2.  The prevalence of occult leiomyosarcoma at surgery for presumed uterine fibroids: a meta-analysis.

Authors:  Elizabeth A Pritts; David J Vanness; Jonathan S Berek; William Parker; Ronald Feinberg; Jacqueline Feinberg; David L Olive
Journal:  Gynecol Surg       Date:  2015-05-19
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.